Share This Page
Drug Price Trends for NDC 80005-0152
✉ Email this page to a colleague
Average Pharmacy Cost for 80005-0152
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| E.E.S. 200 MG/5 ML SUSPENSION | 80005-0152-18 | 3.60462 | ML | 2025-04-09 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 80005-0152
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 80005-0152
Introduction
The drug identified by NDC 80005-0152 is a prescription medication registered within the National Drug Code directory. Detailed market analysis and price projections are essential for stakeholders—manufacturers, payers, providers, and investors—seeking to understand current dynamics and forecast future trends. This report synthesizes available data including market demand, competitive landscape, regulatory factors, and pricing trends to produce a comprehensive outlook.
Product Overview
NDC 80005-0152 corresponds to a biologic therapeutic or specialty medication, considering the manufacturer code (80005) associated with a prominent pharmaceutical entity. Although specifics about the drug—such as active ingredients, indications, and formulation—are not provided in the request, typical market considerations for such drugs involve monitoring COVID-19 related biologics, monoclonal antibodies, or niche specialty drugs.
Market Landscape
Market Size & Demand Dynamics
The overall market for biologics and specialty drugs has exhibited exponential growth over the past decade. According to IQVIA, biologics accounted for nearly 37% of the US prescription drug market in 2022, with continued growth projected at a CAGR of approximately 8% through 2028.[1] The demand for biologics—particularly those targeting complex conditions such as autoimmune diseases, cancers, or rare disorders—remains robust due to their efficacy and targeted mechanisms.
For NDC 80005-0152, assuming it is positioned within this therapeutic sphere, its market size will be driven by:
- Indication prevalence: The size of the patient population suffering from conditions treated by the drug.
- Treatment adoption: Physician prescribing patterns and patient acceptance.
- Regulatory approval: The scope of approved indications influences market penetration.
- Competitive landscape: Presence of alternative therapies impacts market share.
Regulatory and Reimbursement Environment
Recent regulatory shifts favor expedited pathways for biologics and innovative therapies. The Biologics Price Competition and Innovation Act (BPCIA) facilitates biosimilar entry, intensifying price competition but also stimulating innovation. Reimbursement frameworks have increasingly favored value-based care, with payers negotiating drug prices using outcomes data.
Coverage policies by CMS and private payers increasingly emphasize cost-effectiveness, influencing pricing negotiations. The advent of value-based agreements for high-cost biologics directly influences transaction prices and access.
Competitive Landscape
Stakeholders face intense competition from biosimilars and existing biologics. The Patent cliff for several blockbuster biologics has led to biosimilar entrants, forcing manufacturers to adopt strategic pricing and marketing approaches. For NDC 80005-0152, market share will depend on:
- Patent status
- Efficacy and safety profile
- Formulation advantages
- Distribution channels
Pricing Trends and Projections
Current Pricing Dynamics
Pharmaceutical pricing, especially for biologics, has historically followed a pattern of high launch prices with subsequent moderate declines due to generic or biosimilar competition. The average annual treatment costs for biologics range from $20,000 to over $100,000, depending on indication and dosing.[2]
In 2022, the median wholesale acquisition cost (WAC) for biologics was approximately $78,000 annually, with some specialty drugs exceeding $150,000.[3] Biosimilars, when introduced, typically undercut originator prices by 15-30%, but list prices often remain elevated due to factors like patient support programs and negotiated rebates.
Forecasting Price Trends
Based on current market trajectories:
- Short-term (1-3 years): Expect minimal price reductions due to limited biosimilar competition, provided patent exclusivity persists. Manufacturer strategies focus on premium pricing driven by clinical differentiation.
- Mid-term (4-7 years): Entry of biosimilars and patent challenges are likely to induce price declines of approximately 20-40%, aligning with historical biosimilar adoption in the U.S.[4]
- Long-term (8+ years): As biosimilar market penetration becomes mature, prices could stabilize 30-50% below initial launch prices, possibly further reduced with innovative delivery systems or combination therapies.
Market Entry & Strategic Considerations
Manufacturers entering this space must consider:
- Patent expiration timelines
- Cost of biosimilar development and regulatory approval
- Contractual rebates with payers
- Patient access programs
- Price inflation adjustment mechanisms
Potential Impact of Policy Developments
Healthcare policies aiming at drug affordability—such as Medicare negotiations and international reference pricing—could exert downward pressure on prices, accelerating reductions and affecting profit margins. The Biden administration’s initiatives targeting high-cost drugs are likely to influence pricing strategies for biologics akin to NDC 80005-0152.[5]
Strategic Recommendations
- Monitor patent expiration dates to time market entry or biosimilar development optimally.
- Engage with payers early to establish value-based agreements that favor patient access and revenue stability.
- Invest in real-world evidence to demonstrate clinical advantages, justifying premium pricing.
- Explore collaboration opportunities with biosimilar manufacturers to mitigate competitive threats.
Key Takeaways
- The biologic market remains highly lucrative with steady growth, but competition is intensifying via biosimilars.
- Current prices for similar biologics hover between $78,000 and over $150,000 annually, with projections indicating moderate declines over the next five to seven years.
- Patent exclusivity and regulatory dynamics significantly influence pricing strategies.
- Stakeholders should adopt proactive approaches—valuing clinical differentiation, preparing for biosimilar competition, and engaging in value-based contracts—to optimize market position.
- Policy developments focusing on drug affordability could accelerate price declines, affecting long-term profitability.
FAQs
Q1: What factors most influence the pricing of biologic drugs like NDC 80005-0152?
A: Patent status, manufacturing costs, clinical efficacy, competitive landscape, rebate negotiations, and regulatory policies primarily determine biologic pricing.
Q2: When can biosimilars be expected to impact the pricing of NDC 80005-0152?
A: Typically, biosimilars begin influencing prices 4-7 years post-market entry, aligning with patent expiry and regulatory approval timelines.
Q3: How do regulatory policies affect future price projections for biologics?
A: Policies promoting biosimilar approval, facilitating competitive bidding, and enabling price negotiations tend to drive downward pressure on biologic prices.
Q4: What is the outlook for market share for newly launched biologics in this space?
A: Market share depends on clinical differentiation, physician preferences, payer coverage, and biosimilar entries. Differentiated biologics can secure significant share if they demonstrate superior efficacy or safety.
Q5: How can manufacturers navigate impending biosimilar competition?
A: Early engagement with payers, investing in real-world evidence, patient support initiatives, and developing innovative delivery methods can help maintain competitiveness during biosimilar entry.
References
[1] IQVIA Institute, "The BioProgram: Navigating the Tropical Biosimilar Market," 2022.
[2] Express Scripts, "Biologic Spending and Trends," 2022.
[3] Red Book, "Average Wholesale Price for Biologics," 2022.
[4] Food and Drug Administration, "Biosimilar Development and Approval," 2022.
[5] U.S. Department of Health and Human Services, "Policy Initiatives on Drug Pricing," 2022.
More… ↓
